Intelligent Bio Solutions (NASDAQ:INBS) and Sera Prognostics (NASDAQ:SERA) Head-To-Head Survey

Intelligent Bio Solutions (NASDAQ:INBS) and Sera Prognostics (NASDAQ:SERA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, profitability, dividends, earnings, risk and institutional ownership.

Analyst Recommendations

This is a breakdown of current ratings for Intelligent Bio Solutions and Sera Prognostics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intelligent Bio Solutions	1	0	0	0	1.00
Sera Prognostics	1	0	0	1	2.50

Sera Prognostics has a consensus price target of $5.00, indicating a potential upside of 166.81%. Given Sera Prognostics’ stronger consensus rating and higher probable upside, analysts plainly believe Sera Prognostics is more favorable than Intelligent Bio Solutions.

Institutional and Insider Ownership

33.0% of Intelligent Bio Solutions shares are owned by institutional investors. Comparatively, 54.6% of Sera Prognostics shares are owned by institutional investors. 1.3% of Intelligent Bio Solutions shares are owned by company insiders. Comparatively, 11.3% of Sera Prognostics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Intelligent Bio Solutions and Sera Prognostics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intelligent Bio Solutions	$3.58 million	1.30	-$10.57 million	($14.82)	-0.16
Sera Prognostics	$80,000.00	916.85	-$31.93 million	($0.68)	-2.76

Intelligent Bio Solutions has higher revenue and earnings than Sera Prognostics. Sera Prognostics is trading at a lower price-to-earnings ratio than Intelligent Bio Solutions, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Intelligent Bio Solutions has a beta of 4.24, meaning that its stock price is 324% more volatile than the S&P 500. Comparatively, Sera Prognostics has a beta of 0.92, meaning that its stock price is 8% less volatile than the S&P 500.

Profitability

This table compares Intelligent Bio Solutions and Sera Prognostics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Intelligent Bio Solutions	-315.33%	-200.68%	-97.31%
Sera Prognostics	-39,417.29%	-37.50%	-29.02%

Summary

Sera Prognostics beats Intelligent Bio Solutions on 9 of the 14 factors compared between the two stocks.

About Intelligent Bio Solutions

Intelligent Bio Solutions Inc., a medical technology company, developing non-invasive, real-time monitoring, and diagnostic tests for patients and their primary health practitioners. It offers saliva glucose biosensor for diabetes management that measures glucose in saliva. The company also provides intelligent fingerprinting drug screening system, a revolutionizing portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields; and biosensor platform for biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022. The company was incorporated in 2016 and is headquartered in New York, New York. Intelligent Bio Solutions Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.

About Sera Prognostics

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.